FFF Enterprises: BioSupply Trends Newsletter
Monday, March 19, 2018

FDA Chooses Influenza Vaccine Strains for the 2018-19 Season

 

In this Issue

•  IVIG/Albumin Supply Index
•  Open Market Pricing
•  New Products from FFF
•  Current Medicare
IVIG / SCIG Rates
•  Resources
•  Subscribe to IG Living and BioSupply Trends Quarterly
 

The U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee has chosen the Northern Hemisphere’s 2018-19 influenza vaccine strains based on the World Health Organization’s recommendations on Feb. 22. [ read more ]

Heart Failure Death Risk Drops 50% in Those Who Receive Flu Vaccines

A new study shows people with heart failure who receive a seasonal influenza vaccine have a 50 percent drop in the risk of death during flu season and a 20 percent drop in the risk of death during the rest of the year. [ read more ]

Study Finds Vaccines Don’t Weaken Babies’ Immune Systems

In response to concerns from parents about whether multiple vaccines in early childhood could weaken their children’s immune system, researchers conducted a study that examined whether the vaccine schedule was associated with an increased risk of infections not targeted by vaccines and found no statistically significant differences in estimated cumulative vaccine antigen exposure through the first 23 months of life. [ read more ]

Industry News

 
 

From CSL Behring

CSL Behring is discontinuing Monoclate-P (antihemophilic factor [human], factor VIII). According to a company statement, "as hemophilia A treatment has advanced, and patients have transitioned from plasma-derived to recombinant and longer-acting therapies, it has been increasingly difficult to sustain the production and distribution of Monoclate-P." CSL estimates supply will be available through December 2018, which gives providers time to consider different treatment options for patients. [ read more ]

From CSL Behring

CSL Behring is discontinuing the production of Carimune NF (immune globulin [human] nanofiltered) in the third quarter of 2018 due to the preference among healthcare professionals and patients for newer, more advanced immune globulin options.  [ read more ]

From AstraZeneca

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices has voted 12-2 to recommend FluMist, the nasal spray version of the influenza vaccine, be used during the 2018-19 influenza season. [ read more ]

IVIG & Albumin Supply Index

 
 
 

MyFluVaccine Loyalty Program

Want priority access on flu vaccines
for the 2019-2020 season?

Then take advantage of our NEW inclusive MFV Loyalty Program and enroll for the 2019-2020 season when you go to book your flu vaccine orders for the 2018-2019 season through MyFluVaccine.com

  • Priority access on advance released flu vaccines
  • No minimum purchase
  • Hassle-free
  • Guaranteed booking for the products you need

What's New at FFF

HEPLISAV-B (DYNAVAX TECHNOLOGIES CORP.)

HEPLISAV-B (hepatitis B vaccine [recombinant] adjuvanted) is indicated in adults ages 18 and older for prevention of infection caused by all known subtypes of hepatitis B virus. It is supplied in 0.5 mL single-dose vials.

For more information about HEPLISAV-B, login to biosupply.fffenterprises.com

REBINYN (NOVO NORDISK)

REBINYN (glycoPEGylated) is a recombinant DNA-derived coagulation factor IX concentrate indicated for use in adults and children with hemophilia B for on-demand treatment and control of bleeding episodes and perioperative management of bleeding. It is available as a lyophilized powder in single-use vials of 500, 1,000 and 2,000 IU.

For more information about REBINYN, login to biosupply.fffenterprises.com

These products can be ordered from FFF Enterprise's BioSupply Online Ordering System or by calling
Wow! Customer Care at (800) 843-7477.

Current Medicare IVIG / SCIG Rates

Rates per gram are effective Jan. 1, 2018, through Mar. 31, 2018.

 
Product J Codes ASP + 6%
(before sequester)
ASP + 4.3%*
(after sequester)
IVIG
Carimune NF J1566 $68.83 $67.73
Flebogamma J1572 $67.31 $66.23
Gammagard S/D J1566 $68.83 $67.73
Gammaplex J1557 $77.62 $76.37
Octagam J1568 $71.18 $70.04
Privigen J1459 $76.96 $75.73
SCIG
CUVITRU J1555 $137.89 $135.68
Hizentra J1559 $98.31 $96.73
HyQvia J1575 $140.63 $138.37
IVIG / SCIG
Gammagard Liquid J1569 $81.45 $80.14
Gammaked J1561 $81.41 $80.10
Gamunex-C J1561 $81.41 $80.10

*Reflects 2% sequestration reduction applied to 80% Medicare payment portion as required under Budget Control Act of 2011.

 

Resources

FFF customers may order the following complementary resources to help you with your practice:

•  IG Immune Globulin (Human)
•  Hyperimmune Globulins
•  Anti-Inhibitor, Factor VIIa & IX
•  Factor VIII & von Willebrand Factor
•  Seasonal Influenza Vaccine

Subscribe to IG Living

IG Living is the only magazine for the immune globulin (IG) community for patients who suffer from chronic illness and their caregivers.

Subscribe to BioSupply
Trends Quarterly

BioSupply Trends Quarterly magazine is the definitive source for industry trends, news and information for the biopharmaceuticals marketplace.

Home | About | Advertise | Subscribe | Contact – ©2018 FFF Enterprises, Inc.
This email was sent by: %%Member_Busname%%, %%Member_Addr%% %%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%
Manage preferences: Privacy Policy, Update Profile, Unsubscribe.